



## Request for Applications: Pilot Award Funds in Human Immunobiology

The Mucosal and Vaccine Research Colorado (MAVRC) program is soliciting applications for pilot award funding for collaborative human immunobiology studies. MAVRC promotes new interactions between a diverse spectrum of researchers to explore mucosal and vaccine biology and disease. Our goal is to foster and facilitate the development of innovative collaborative, interdisciplinary biomedical research programs applicable to human mucosal biology, immunology and vaccine development.

### Eligibility

Applicant teams will include basic and clinical faculty investigators, with an emphasis on new interdepartmental or inter-institutional collaborations. Academic researchers must become MAVRC members in order to apply. To access the simple application, click the "Join MAVRC" button on webpage <http://ucdenver.edu/MAVRC>. A free membership entitles you to access to pilot funding opportunities, administrative support for new research and funding, shared sponsorship for speakers, and participation in a statewide collaborative research network.

Proposals will represent new and creative projects investigating human immunobiology, supported by a concrete plan for specific subsequent external funding. Submissions will be reviewed by the MAVRC Board of Directors for significance, innovation, approach, and budget. Relevant IRB approval must be attained prior to the award allocation.

Two innovative pilot projects will be selected to receive a \$20,000 award for studies to be conducted within a one year period, with no carryover. The awards will cover direct costs only, including supplies, (non Principal Investigator) salaries, patient costs, and should not supplement other grants.

### Applications

Applications are due October 1, 2010 in PDF form emailed to [MAVRC@ucdenver.edu](mailto:MAVRC@ucdenver.edu). A three-page proposal (covering numbers 2-6; Arial 11 font) in NIH format will include:

1. Cover page (Title and Investigators)
2. Hypotheses
3. Specific Objectives
4. Background, including special significance
5. Work proposed
6. Plan for subsequent funding
7. IRB plan for protection of human subjects (approval due prior to funding)
8. Budget (direct costs only; no indirect costs provided) (one page)
9. NIH biosketch of each Investigator

### Notification of Awards

Selected awardees will be announced November 15, 2010. Brief summary statements will be provided. Funding commences with IRB approval.

**Mucosal and Vaccine Research Colorado**  
University of Colorado Denver  
12631 E. 17<sup>th</sup> Ave, Room 7408  
Aurora, CO 80045  
<http://ucdenver.edu/MAVRC>

#### Scientific Inquiries:

Edward Janoff, MD – Director  
[Edward.Janoff@ucdenver.edu](mailto:Edward.Janoff@ucdenver.edu)

#### Administrative Inquiries:

Carola Hagenau – Program Administrator  
[Carola.Hagenau@ucdenver.edu](mailto:Carola.Hagenau@ucdenver.edu)